Elite AI Partnership with Novartis
Yseop has been named among only seven elite AI partners by Novartis, aiming to reduce R&D cycle time by six months. This collaboration, highlighted during the Novartis Management Investor Event, signals a major shift toward integrating Generative AI into core pharmaceutical operations.
AI Writing Assistant Revolutionizes Submissions
Yseop’s flagship tool, Yseop Copilot, supported more than 165 clinical trials in 2024. By automating the creation of Clinical Study Reports, patient narratives, and summaries, it helps pharmaceutical companies cut submission times and accelerate access to life-saving therapies.
Government-Backed Innovation Momentum
Yseop secured funding through France’s i-Nov Innovation Contest, co-managed by Bpifrance. This public-sector recognition supports the advancement of its hybrid Natural Language Generation platform, blending symbolic AI, machine learning, and LLMs for highly accurate, scalable regulatory writing.
Strategic Tech Alliances Expand Global Reach
Key alliances with AWS, Veeva, and Cognizant are helping scale Yseop’s solutions globally. The company is listed on AWS Marketplace and part of the AWS ISV Accelerate Program. Integration with Veeva Vault RIM allows seamless document creation, while its collaboration with Cognizant ensures AI-driven productivity across enterprise pharma operations.
About Yseop
Yseop is a global leader in Generative AI for regulated industries, transforming scientific and regulatory content automation with a human-centric AI platform. With hybrid NLG technology and a suite of enterprise-ready applications, Yseop empowers pharma companies to accelerate development and compliance at scale. Visit: https://www.yseop.com
By